Spironolactone Use in Pregnancy

Introduction to Spironolactone Risks

Spironolactone poses significant risks during pregnancy due to its anti-androgenic activity, which can cause feminization and other adverse fetal outcomes, especially in male fetuses, and its use should be avoided 1, 2, 3
The medication crosses the placenta and can directly affect the developing fetus, posing significant risks through anti-androgenic activity, even at doses less than 50 mg/day 2, 3

Spironolactone should be discontinued before conception, allowing for complete elimination of the drug and normalization of hormonal parameters, with a recommended washout period similar to that of other teratogenic medications like methotrexate (3 months) 1
Patients should be counseled about the potential risks and need for close monitoring of fetal development if exposed to spironolactone during pregnancy, and the importance of planning ahead for medication changes before conception 2, 1

For hypertension during pregnancy, safer alternatives like methyldopa, labetalol, or nifedipine should be used, as recommended by the American Heart Association and the European Society of Cardiology 1, 4
For heart failure during pregnancy, hydralazine, nitrates, and certain beta-blockers (metoprolol) are preferred alternatives, according to the European Society of Cardiology and the American Heart Association 1, 4
For acne/hormonal conditions during pregnancy, treatment should be postponed until after delivery or safer alternatives should be considered, as suggested by the American Academy of Dermatology 5

If a woman becomes pregnant while taking spironolactone, immediate discontinuation of the medication and referral for obstetric counseling to discuss potential risks are recommended, with consideration of detailed ultrasound to evaluate for any genital abnormalities in male fetuses 1, 2, 3

While spironolactone itself is not present in breast milk, its active metabolite canrenone is detected in low amounts, with limited data suggesting no adverse effects on breastfed infants after short-term exposure, although long-term effects remain unknown, and guidelines from the Academy of Breastfeeding Medicine may provide further recommendations 1

The FDA classifies spironolactone as Pregnancy Category C, indicating potential risks based on animal reproduction studies, and recommends avoiding its use in pregnant women or advising pregnant women of the potential risk to male fetuses 3
All major dermatology guidelines, including those from the American Academy of Dermatology, contraindicate the use of spironolactone during pregnancy 2, 3, 5
The American College of Obstetricians and Gynecologists, the American Heart Association, and the European Society of Cardiology provide guidelines for the management of spironolactone use during pregnancy, emphasizing the importance of avoiding its use and using alternative treatments when necessary 1, 4